Payment overview · 2025
General Payments
$681.11
32 reported records · 9 companies
Healthcare provider profile · identity verified
Quentin B Emerson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FORT BRANCH, IN · NPI 1427065341
Verified facts
What the public records show
CMS Open Payments records show Quentin B Emerson, M.D. received $681.11 in general payments during 2025 across 32 reported records.
Novo Nordisk Inc accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $225.73 | 33.1% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $188.38 | 27.7% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.63 | 12.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77.58 | 11.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.96 | 4.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.56 | 3.0% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $18.51 | 2.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.44 | 2.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.32 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $636.11 | 31 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $188.38 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $164.67 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $88.79 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $77.58 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $77.58 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.63 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.63 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 314 | 64 |
| Lisinopril | Lisinopril | 307 | 51 |
| Gabapentin | Gabapentin | 273 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 49 |
| Meloxicam | Meloxicam | 235 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 26 |
| Metformin Hcl | Metformin Hcl | 162 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 29 |
| Clonazepam | Clonazepam | 151 | 16 |
| Omeprazole | Omeprazole | 147 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 142 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 17 |
| Allopurinol | Allopurinol | 124 | 20 |
| Lorazepam | Lorazepam | 123 | 17 |
| Ozempic | Semaglutide | 123 | 25 |
| Azithromycin | Azithromycin | 121 | 79 |
| Furosemide | Furosemide | 120 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 21 |
| Potassium Chloride | Potassium Chloride | 103 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 24 |
| Sertraline Hcl | Sertraline Hcl | 98 | 16 |
| Trazodone Hcl | Trazodone Hcl | 97 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 18 |
| Pregabalin | Pregabalin | 91 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 21 |
| Risperidone | Risperidone | 87 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 13 |
| Buspirone Hcl | Buspirone Hcl | 83 | 12 |
| Tramadol Hcl | Tramadol Hcl | 83 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 11 |
| Losartan Potassium | Losartan Potassium | 74 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 65 | suppressed |
| Simvastatin | Simvastatin | 65 | 17 |
| Levetiracetam | Levetiracetam | 64 | suppressed |
| Famotidine | Famotidine | 63 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 45 |
| Vascepa | Icosapent Ethyl | 62 | 12 |
| Ezetimibe | Ezetimibe | 58 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 58 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 53 | suppressed |
| Levofloxacin | Levofloxacin | 50 | 21 |
| Carvedilol | Carvedilol | 48 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 47 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Glimepiride | Glimepiride | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | suppressed |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Acyclovir | Acyclovir | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Prednisone | Prednisone | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 23 |
| Diazepam | Diazepam | 39 | suppressed |
| Eliquis | Apixaban | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 11 |
| Olanzapine | Olanzapine | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 14 |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Rybelsus | Semaglutide | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Haloperidol | Haloperidol | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Nucynta | Tapentadol Hcl | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Nystatin | Nystatin | 24 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 16 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tenormin | Atenolol | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $681.11 · 32 records | Novo Nordisk Inc | Auvelity, ELIQUIS, MOUNJARO, Miro3D, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, Wegovy, XIFAXAN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error